Triple-positive patients (both ER/PR-positive and HER2-positive) could also benefit from dual blockage.290,291 Nearly 50% of the breast cancers with HER2 amplification also have some expression of hormone receptor and there is significant cross talk between them.29,292,293. Here, ERBB2 is linked to breast carcinoma.